JP2019525923A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525923A5
JP2019525923A5 JP2019503485A JP2019503485A JP2019525923A5 JP 2019525923 A5 JP2019525923 A5 JP 2019525923A5 JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019525923 A5 JP2019525923 A5 JP 2019525923A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
delivered
eye
des
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503485A
Other languages
English (en)
Japanese (ja)
Other versions
JP6889771B2 (ja
JP2019525923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/042382 external-priority patent/WO2018017479A1/en
Publication of JP2019525923A publication Critical patent/JP2019525923A/ja
Publication of JP2019525923A5 publication Critical patent/JP2019525923A5/ja
Application granted granted Critical
Publication of JP6889771B2 publication Critical patent/JP6889771B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503485A 2016-07-18 2017-07-17 ドライアイ症候群を治療する方法 Active JP6889771B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363565P 2016-07-18 2016-07-18
US201662363592P 2016-07-18 2016-07-18
US62/363,592 2016-07-18
US62/363,565 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (3)

Publication Number Publication Date
JP2019525923A JP2019525923A (ja) 2019-09-12
JP2019525923A5 true JP2019525923A5 (cg-RX-API-DMAC7.html) 2019-10-24
JP6889771B2 JP6889771B2 (ja) 2021-06-18

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503485A Active JP6889771B2 (ja) 2016-07-18 2017-07-17 ドライアイ症候群を治療する方法

Country Status (7)

Country Link
US (2) US10960051B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484497A4 (cg-RX-API-DMAC7.html)
JP (1) JP6889771B2 (cg-RX-API-DMAC7.html)
KR (1) KR102488796B1 (cg-RX-API-DMAC7.html)
CN (1) CN109789182A (cg-RX-API-DMAC7.html)
AU (1) AU2017300268B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018017479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655919B2 (en) 1990-02-22 1995-01-19 Macnaught Pty Limited Artificial tears
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ4(Tβ4)、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
CN101549148A (zh) * 2001-08-29 2009-10-07 雷根内克斯生物制药有限公司 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用
WO2006076588A1 (en) * 2005-01-13 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
KR20080018268A (ko) * 2005-06-17 2008-02-27 리지너크스 바이오 파마소티컬스, 인코포레이티드 조직 악화, 부상 또는 손상을 치료하거나 또는 예방하기위한 엘케이케이티이티 및/또는 엘케이케이티엔티 조성물들및 그 방법
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders

Similar Documents

Publication Publication Date Title
Hyttinen et al. Mitochondrial quality control in AMD: does mitophagy play a pivotal role?
US11458189B2 (en) Cytoprotective drugs
PE20241305A1 (es) Analogos de amilina
Ji et al. Resveratrol attenuates retinal ganglion cell loss in a mouse model of retinal ischemia reperfusion injury via multiple pathways
TWI670057B (zh) 治療乾眼用滴眼劑
JP2018531233A5 (cg-RX-API-DMAC7.html)
Zhang et al. Doxycycline alleviates paraquat-induced acute lung injury by inhibiting neutrophil-derived matrix metalloproteinase 9
CN104940926B (zh) 重组融合蛋白制剂
Vavrinec et al. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat
RU2015128496A (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
IL273531B1 (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
JP2021515758A5 (cg-RX-API-DMAC7.html)
JP2015025011A5 (cg-RX-API-DMAC7.html)
Imai et al. Triamcinolone acetonide suppresses inflammation and facilitates vascular barrier function in human retinal microvascular endothelial cells
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
UA126941C2 (uk) Фармацевтичні композиції для інгібування запальних цитокінів
CN102066402A (zh) 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
JP2018526412A5 (cg-RX-API-DMAC7.html)
Zhou et al. The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns
AR079683A1 (es) Formulacion topica oftalmica de peptidos
ES2899759T3 (es) Composición hiperosmolar de ácido hialurónico
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
JP2018500546A5 (cg-RX-API-DMAC7.html)
JP2021512847A (ja) キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤
MA50991A (fr) Composition ophtalmique topique comprenant de l'acide dobésilique pour le traitement de maladies du segment postérieur de l'oeil